Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD1 | P28347 | 3/20 | 0.57 |
| ▸ | YAP1 | P46937 | 1/20 | 0.57 |
| ▸ | BRD4 | O60885 | 6/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | TNNI3K | Q59H18 | 5/20 | 0.33 |
| ▸ | PARG | Q86W56 | 2/20 | 0.32 |
| ▸ | TLR2 | O60603 | 1/20 | 0.32 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.32 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25790424 | 1.00 | TEAD1 (0.57) | TEAD1YAP1BRD4F10TNNI3K | |
| SCHEMBL20779718 | 0.84 | TEAD1 (0.60) | TEAD1YAP1BRD4TNNI3KTLR2 | |
| SCHEMBL22635634 | 0.84 | TEAD1 (0.60) | TEAD1YAP1BRD4TNNI3KTLR2 | |
| SCHEMBL20779716 | 0.84 | TEAD1 (0.60) | TEAD1YAP1BRD4TNNI3KTLR2 | |
| SCHEMBL29648372 | 0.84 | TEAD1 (0.60) | TEAD1YAP1BRD4TNNI3KTLR2 | |
| SCHEMBL24496071 | 0.81 | TEAD1 (0.59) | TEAD1YAP1BRD4TNNI3K | |
| SCHEMBL24496073 | 0.81 | TEAD1 (0.59) | TEAD1YAP1BRD4TNNI3K | |
| SCHEMBL26669265 | 0.81 | TEAD1 (0.59) | TEAD1YAP1BRD4TNNI3K | |
| SCHEMBL24496258 | 0.81 | TEAD1 (0.59) | TEAD1YAP1BRD4TNNI3K | |
| SCHEMBL20766526 | 0.74 | YAP1 (0.57) | TEAD1YAP1BRD4SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | TEAD1 1/4885YAP1 9/4885BRD4 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.